SAR-446309

N/A

Report date: 2026/03/19 17:03:31

Base Information

Drug NameSAR-446309
Drug Alias NameAMX-818HER2-XPATSAR-446309VIR-5818
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsAnti-CD3
TargetsReceptor protein-tyrosine kinase erbB-2T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmunix Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofiVir Biotechnology IncAmunix Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A